Corporate Overview

Founded on the principle that strong science would lead to important new medicines, Regeneron has become an integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.

Regeneron currently markets ARCALYST^® (rilonacept) Injection for Subcutaneous Use for the treatment of a rare, inherited, inflammatory condition. Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, age-related macular degeneration, central retinal vein occlusion, and certain cancers. Additional therapeutic candidates are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic conditions, and cancer.

The Company's ability to develop product candidates is enhanced by the application of several proprietary technologies that Regeneron has incorporated into a comprehensive drug discovery and development process. This process is designed to thoroughly understand the biology of specific diseases, discover potential therapeutic candidates, and evaluate these candidates in clinical trials. One specific area of Regeneron expertise is the rapid development of fully-human monoclonal antibodies. In November 2007, Regeneron and sanofi-aventis entered into a global, strategic collaboration to discover, develop, and commercialize fully-human therapeutic antibodies utilizing Regeneron's proprietary VelociSuite&trade of technologies, and we expanded the collaboration in November 2009. Five human antibodies developed under the sanofi-aventis collaboration are in clinical development today, with a goal of advancing an average of four to five new antibodies into clinical development each year through 2017.

In addition to the Company's corporate headquarters and research laboratories in Tarrytown, New York, Regeneron has a large-scale biologics manufacturing facility in Rensselaer, New York, where it produces commercial and investigational products for its clinical trials, and a satellite office in Bridgewater, New Jersey.